Dr. Chenyang Xu Appointed President and Co-Chairman of PVmed, Steering the Company into a New Era of AI-Powered Oncology Innovation
In May 2017, guided by the original aspiration of “empowering through technology, serving physicians, and benefiting patients,” Lu Yao and Shen Shuo, fellow alumni of the University of Science and Technology of China (USTC), co-founded Baishi Medical. In October of the same year, they successfully invited Dr. Xu Chenyang, a distinguished USTC alumnus and seasoned industry expert, to join as a Managing Partner and Chief Scientific Advisor.Drive the company's medium- and long-term product development roadmap, providing guidance and recommendations for daily operations.
Since its founding several years ago, Baishi Medical has maintained steady growth through continuous technological breakthroughs and product innovation, earning widespread recognition and acclaim from clinical experts. The company has received numerous industry awards and honors, and in August 2021, it successfully closed a nearly RMB 100 million Series A financing round led by Cheno Chentu and Philips, marking a smooth transition from the incubation stage to the growth stage.
Following the completion of its Series A financing, Baishi Medical has reached a new level in its overall development. As market operations expand and the team grows, Baishi Medical is actively exploring effective measures to enhance operational quality and efficiency, leveraging this momentum to build a more standardized and structured organization. After deliberation by the management team and approval by the Board of Directors, the roles of three managing partners have been optimized and adjusted as follows:
Dr. Chenyang Xu has been appointed as President and Co-Chairman, Professor Yao Lu as Chief Technology Officer (CTO) and Co-Chairman, while Dr. Shuo Shen continues to serve as Chief Executive Officer (CEO).
As the core architect of the PVmed 2.0 innovation strategy, Dr. Xu Chenyang boasts nearly three decades of extensive experience in research, development, management, and investment in world-leading AI medical imaging.He is also the proposer of Gradient Vector Flow (GVF), an important foundational method in the field of computer vision, and the inventor of more than 40 international patents. He led the development of over a dozen products, including CartoMerge, the world’s first commercial artificial intelligence-based 3D cardiac imaging-guided mapping system, jointly developed with Johnson & Johnson.®) generated billions of dollars in new sales for Siemens and its commercial partners, while serving millions of patients worldwide. Dr. Xu has also been recognized for his outstanding contributions to the fields of computer vision and medical imaging applications research,He was named an IEEE Fellow, the highest honor conferred by the Institute of Electrical and Electronics Engineers (IEEE), making him one of the earliest Chinese experts to achieve this distinction in the field of medical imaging applications.
In 2000, Dr. Xu joined Siemens Corporate Research in the United States. In 2001, he co-founded the Siemens Interventional Imaging Laboratory, serving as its Technical Lead and Director. In 2005, he concurrently assumed the role of Co-Founding Executive Director at the Siemens China Medical Imaging Verification and Application Center. In 2009, Dr. Xu was promoted to Chief Technology Officer of the Siemens Silicon Valley Innovation Center, and in 2010, he became its General Manager, making him the highest-ranking Chinese executive at Siemens in the United States. During his tenure, he led the center in providing new venture incubation, acceleration, and capital support to nearly one hundred high-tech startups across the globe, including in the United States, Canada, Germany, the United Kingdom, and Israel. The center has been widely regarded as a model for corporate innovation among large enterprises in Europe, America, and Asia, with companies such as Intel, Samsung, and Dyson considering it a benchmark for learning. Since 2018, he has served as a Co-Founding Partner of the Silicon Valley Future Institute and a Managing Partner at Mingdao Future Capital. He is also a Guest Lecturer for the EMBA program in the Department of Economics and Management at Tsinghua University, and a Professor delivering masterclasses on corporate innovation and digital transformation for Silicon Valley study tours organized by various business schools, including Cheung Kong Graduate School of Business and the National University of Singapore.
In addition to his extensive experience in product R&D and innovation, mature team management capabilities, and strategic planning acumen for tech startups, Dr. Xu Chenyang has also been deeply involved in the overall business planning and execution as well as corporate culture development at Baishi Medical. His appointment as President and Co-Chairman of Baishi Medical has significantly boosted the confidence, enthusiasm, and proactivity of all Baishi employees.
Since assuming office,Dr. Xu streamlined the organizational structure and operational processes of Baishi Medical. In the PVmed 2.0 innovative strategic planning, leveraging the accumulated achievements in existing integrated intelligent diagnosis and treatment products, the company precisely focuses on the AI-driven oncology treatment sector, which features higher entry barriers.It has successively introduced management talent and industry experts from leading domestic and international medical AI enterprises, making forward-looking plans across multiple dimensions—including team building, product technology, market sales, and corporate development strategy—to guide and drive Baishi Medical, a new venture, toward the gradual realization of refined management and lean operations.
According to data from the National Cancer Center, malignant tumors account for 23.91% of all causes of death among residents in China. Cancer has become the leading cause of death in the country, with the number of new cases continuing to rise annually. The 2020 report from the National Health Commission indicates that the current five-year survival rate for cancer patients in China is approximately 40.5%. This figure still lags significantly behind the 70% rate observed in the United States and many other developed countries, underscoring that the fight against cancer remains a long and arduous endeavor.
As PVmed continues to deepen its roots in the oncology treatment industry, its founding mission—"Empowering through technology, serving physicians, and benefiting patients"—remains as strong as ever. Embarking on the new journey of PVmed 2.0, all members of PVmed, under the leadership of the new helmsman, will leverage innovative technologies to fully empower precision oncology care, promote high-quality development of cancer treatment in China, and contribute to the national initiative for smart healthcare.
Xu Chenyang, President and Co-Chairman of Bosh Medical：I am deeply honored by the Board of Directors’ recognition and appointment. The demand for and market size of oncology medical services in China are growing steadily. As a leader in the AI-driven oncology treatment sector, Bosh Vision Medical boasts extensive industry experience and significant market opportunities, having achieved numerous outstanding translational outcomes and delivered excellent user experiences over the past few years. I am delighted to work with such an outstanding and professional team, and I look forward to scaling new heights together in this new phase, jointly driving the development of Bosh Vision Medical, creating greater value, and making more substantial contributions to the advancement of precision oncology treatment.
Lu Yao, Founder and Co-Chairman of Bosh Medical:Dr. Xu Chenyang is the ideal leader to guide PVmed into the new phase of PVmed 2.0 at an optimal pace. His advanced management philosophy, extensive execution experience, and pragmatic work style will accelerate the implementation and rollout of PVmed’s strategic initiatives and key operational projects. Upon assuming his role, Mr. Xu will be better positioned to integrate corporate resources and coordinate internal development. Under his leadership, PVmed is poised to embark on a brand-new chapter.
Shen Shuo, Co-founder and CEO of Baishi Medical:Dr. Xu Chenyang previously served as a Director and Partner at Bosh Medical, providing constructive guidance on strategic planning and the incubation of key products. He has now officially assumed the role of President on a full-time basis, where he will lead Bosh Medical in achieving rapid advancements and breakthroughs in specialization and internationalization, with the aim of establishing it as a globally leading medical technology company.